Anti-peptic ulcer drug that can be given in patients with chronic renal failure (CRF)
**Core Concept**
In patients with chronic renal failure (CRF), the management of peptic ulcer disease requires careful selection of medications that do not accumulate to toxic levels due to reduced renal clearance. The primary concern is the potential for drug-induced hyperkalemia, acid-base disturbances, and electrolyte imbalances.
**Why the Correct Answer is Right**
Misoprostol is a synthetic prostaglandin E1 analogue that is used to prevent NSAID-induced gastric ulcers and treat peptic ulcers. It is a suitable option in patients with CRF because it is primarily excreted via the bile and does not require dose adjustment in renal impairment. Misoprostol promotes gastric mucosal protection by increasing the secretion of mucus and bicarbonate, and it does not have a significant impact on potassium levels or acid-base balance.
**Why Each Wrong Option is Incorrect**
* **Option A:** Ranitidine is a histamine H2-receptor antagonist that is commonly used to treat peptic ulcers. However, it can accumulate in patients with CRF, potentially leading to adverse effects such as confusion, hallucinations, and changes in mental status.
* **Option B:** Omeprazole is a proton pump inhibitor that is effective in treating peptic ulcers. However, it is metabolized by the liver and excreted in the urine, and its clearance may be decreased in patients with CRF, leading to potential accumulation and toxicity.
* **Option C:** Sucralfate is a topical protective agent that forms an ulcer-adherent complex to protect the gastric mucosa. However, it can bind to aluminum-containing antacids and phosphate-containing enemas, potentially leading to aluminum toxicity in patients with CRF.
**Clinical Pearl / High-Yield Fact**
In patients with CRF, it is essential to choose medications with a low risk of accumulation and toxicity, and to closely monitor electrolyte and acid-base balance to prevent adverse effects.
**Correct Answer:** D. Misoprostol